28181 A retrospective review of continuation and discontinuation rates of biologic therapy during the COVID-19 pandemic in a single academic center dermatology practice

Abstract

Background: When the COVID-19 pandemic arose, there was considerable fear among prescribers and patients as to the risk for biologic use for cutaneous conditions. Nevertheless, suspending biologics may cause a higher skin disease burden and lack of response when reintroduced.